The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...

Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...

Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and ...

The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty ...

Bumpus replaced agency veteran Janet Woodcock as principal deputy commissioner in February 2024. She was previously the FDA’s ...

While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down ...

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...

The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...